Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Topigen Pharmaceuticals has said that Paul Wotton has resigned from his role as president, CEO and director, and Patricia Lamothe has resigned from her role as CFO. Both executives have left their positions at Topigen to pursue other opportunities.
Subscribe to our email newsletter
Mark Parry-Billings, chief development officer, and Lisa Nolan, senior vice president, Business Development, remain in their leadership roles and will work closely with company’s board of directors to continue to advance development efforts of the company’s portfolio of respiratory products. The board has initiated a search for a new CEO to lead the company through late-stage clinical development.
Barbara Van Oye, company’s director of finance, will continue to manage the company’s financial operations.